Specialty Medical Homes to Improve Outcomes for Patients With IBD and Behavioral Health Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03985800 |
Recruitment Status :
Recruiting
First Posted : June 14, 2019
Last Update Posted : September 9, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Inflammatory Bowel Disease Behavioral Symptoms | Other: TEAM Other: TECH | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 990 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Comparison between technology interventions and in-person interventions. |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Specialty Medical Homes to Improve Outcomes for Patients With IBD and Behavioral Health Conditions |
Actual Study Start Date : | July 1, 2019 |
Estimated Primary Completion Date : | February 28, 2025 |
Estimated Study Completion Date : | January 30, 2026 |
Arm | Intervention/treatment |
---|---|
Active Comparator: TEAM-care as usual approach
Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
|
Other: TEAM
TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist. |
Active Comparator: TECH-telehealth approach
Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
|
Other: TECH
TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools. |
- Inflammatory Bowel Disease Symptom Severity-PROMIS GI [ Time Frame: Compare at Baseline, 6-month and 12-month for any changes ]Patient-Reported Outcomes Measurement Information System Gastrointestinal (PROMIS GI symptoms scale)
- Inflammatory Bowel Disease Symptom Severity-HBI [ Time Frame: Compare at Baseline, 6-month and 12-month for any changes ]Harvey Bradshaw Index
- Inflammatory Bowel Disease Symptom Severity [ Time Frame: Compare at baseline, 6-months and 12-months for any changes ]Ulcerative Colitis Activity Index
- Behavioral Health Symptom Severity [ Time Frame: Compare at baseline, 6-month and12-month for any changes ]Personal Health Questionnaire (PHQ-8)
- Behavioral Health Symptom Severity [ Time Frame: Compare at baseline, 6-month and 12-months for any changes ]General Anxiety Disorder 7 item scale (AD-7)
- Functional Impairment [ Time Frame: Compare at baseline, 6-month and 12-month for any changes ]Short Form 12 Health Survey Version 2- (SF12V2)
- Health Care Utilization [ Time Frame: Compile and compare at baseline, 6-month and 12-months for any changes ]Composite score of Emergency Department visits, unplanned hospitalizations, surgeries, procedures/imaging
- Self-Efficacy [ Time Frame: Compare at baseline, 6-month and 12-month for any changes ]Inflammatory Bowel Disease Self-Efficacy Scale
- Inflammatory Bowel Disease- Related Quality of Life [ Time Frame: Compare at baseline, 6-month and 12-month for any changes ]Short Quality of Life in Inflammatory Bowel Disease Questionnaire- SIBDQ

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Inflammatory Bowel Disease Diagnosis of Crohn's or Ulcerative Colitis. Behavioral health symptoms mild to severe, defined as a score of >= 6 on the Personal Health Questionnaire 4 (PHQ4)
Exclusion Criteria:
- Lack of smart phone, and/or are unable to speak, read or understand English at the minimum-required level.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985800
Contact: Jessica Meyers, MS Ed | 412-454-4023 | meyersj5@upmc.edu |
United States, Pennsylvania | |
University of Pittsburgh Medical Center | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 | |
Contact: Eva Szigethy, MD, PhD 412-802-6696 szigethye@upmc.edu | |
Principal Investigator: Eva Szigethy, MD, PhD |
Principal Investigator: | Eva Szigethy, MD, PhD | University of Pittsburgh Medical Center |
Responsible Party: | Eva Szigethy, Professor of Psychiatry and Medicine, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT03985800 |
Other Study ID Numbers: |
IHS-2017C3-8930 |
First Posted: | June 14, 2019 Key Record Dates |
Last Update Posted: | September 9, 2022 |
Last Verified: | September 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual Participant Data will not be shared. Data is shared at the aggregate level |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Inflammatory Bowel Diseases Behavioral Symptoms Intestinal Diseases |
Gastrointestinal Diseases Digestive System Diseases Gastroenteritis |